NSCLC Therapy Management For Optimal Outcomes

PFIZER, S.A

Object

Topic: Cancer.

Destination: Projects that will be considered for Pfizer support will focus on development of an algorithm or tool to guide the optimal treatment and support of patients with ALK or ROS1 re-arranged NSCLC.

Budget: Up to 150,000$.

Duration: Not Indicated.

Are you interested?

Fill out the form below to receive more information: